Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

The fast pace in which the Trump administration has rolled out changes to how government and businesses operate – a ...

Health scientists and drug industry executives around the world are on alert after the confirmation of Robert F. Kennedy Jr., who spreads antivaccine misinformation and has often derided the ...

The podcast from the Biotechnology Industry Organization, hosted by Rachel King, CEO of BIO. Topics include new innovations, breakthrough research, public policy and industry trends. Available on ...

The firm has claimed that it is the first such vaccine in the world for the highly infectious viral disease that affects ...

South Korean pharmaceutical and biotechnology companies are on edge as U.S. President Donald Trump signals the introduction ...

India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...

The Biotechnology Innovation Organization (BIO ... Penny stocks are notoriously volatile, and so is the biotech industry. Put the two together and you have a recipe for headlines.

SANTA ANA, Calif. - NKGen Biotech, Inc. (NASDAQ: NKGN), a clinical-stage biotechnology company with a current market capitalization of $17 million, has received Fast Track designation from the U.S.

The broader APAC healthcare sector is also expanding rapidly, supported by rising income levels. India's Contract Development and Manufacturing Organization (CDMO) market is poised for exponential ...

Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...